SynBioBeta: Confronting the Problem of Knowledge Mismanagement in Life Science R&D
An article by Synbiobeta delves into the issues of data fragmentation, data analysis and tech transfer in life sciences R&D - with interviews of Chris Stevens, the Director of Strategy, Operations and Planning at GSK, and with Tim Gardner, Riffyn's CEO. From the post:
Today, more resources than ever before are being channeled into life sciences R&D. In recent years, annual worldwide industrial life science R&D spending has exceeded $160 billion and is expected to continue to grow, with government and nonprofit spending on life sciences adding another $60-70B annually to this total. But, contrary to expectations, the influx of support doesn’t mean that researchers’ jobs are getting any easier—and in fact, in some ways they are getting much harder. Read more at synbiobeta.com.
At Riffyn, we take pride in the fact that we are a scientific partner with our customers, not simply a vendor. We are a dedicated, dynamic group of people passionate about helping our customers discover more.